Cooper Companies (NASDAQ:COO) Rating Reiterated by Piper Sandler

Cooper Companies (NASDAQ:COO)‘s stock had its “overweight” rating restated by research analysts at Piper Sandler in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $115.00 price target on the medical device company’s stock. Piper Sandler’s target price would indicate a potential upside of 34.49% from the company’s current price.

A number of other research analysts also recently issued reports on the stock. Robert W. Baird boosted their price objective on shares of Cooper Companies from $116.00 to $118.00 and gave the company an “outperform” rating in a research report on Friday, May 31st. Redburn Atlantic raised shares of Cooper Companies from a “neutral” rating to a “buy” rating and set a $125.00 price objective on the stock in a research report on Tuesday, March 19th. Citigroup upped their target price on shares of Cooper Companies from $108.00 to $116.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research report on Friday, May 31st. Finally, JPMorgan Chase & Co. raised shares of Cooper Companies from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $100.00 to $120.00 in a research report on Wednesday, March 13th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $111.42.

Cooper Companies Trading Down 1.2 %

NASDAQ:COO opened at $85.51 on Wednesday. The company has a quick ratio of 1.14, a current ratio of 1.95 and a debt-to-equity ratio of 0.34. The company has a fifty day moving average of $92.37 and a 200 day moving average of $94.64. The firm has a market capitalization of $17.03 billion, a P/E ratio of 50.23, a P/E/G ratio of 2.14 and a beta of 0.98. Cooper Companies has a 52 week low of $75.93 and a 52 week high of $104.07.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, May 30th. The medical device company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.02. The business had revenue of $942.60 million for the quarter, compared to the consensus estimate of $948.07 million. Cooper Companies had a net margin of 9.11% and a return on equity of 8.87%. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.77 EPS. On average, research analysts predict that Cooper Companies will post 3.57 earnings per share for the current year.

Hedge Funds Weigh In On Cooper Companies

A number of hedge funds have recently bought and sold shares of the company. Massmutual Trust Co. FSB ADV boosted its stake in Cooper Companies by 18.7% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 996 shares of the medical device company’s stock worth $87,000 after purchasing an additional 157 shares in the last quarter. First Hawaiian Bank bought a new position in Cooper Companies during the 2nd quarter valued at about $1,443,000. GAMMA Investing LLC lifted its stake in Cooper Companies by 30.1% during the 2nd quarter. GAMMA Investing LLC now owns 2,510 shares of the medical device company’s stock valued at $219,000 after acquiring an additional 580 shares during the period. American Trust lifted its stake in Cooper Companies by 282.0% during the 1st quarter. American Trust now owns 2,590 shares of the medical device company’s stock valued at $263,000 after acquiring an additional 1,912 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its stake in Cooper Companies by 337.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 5,347 shares of the medical device company’s stock valued at $543,000 after acquiring an additional 4,125 shares during the period. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.